SENN AB Share Price Nasdaq Stockholm
Equities
SE0010219626
Biotechnology & Medical Research
Sales 2024 * | 67.35M 6.29M 0 495M | Sales 2025 * | 91.85M 8.57M 0 675M | Capitalization | 225M 21.04M 0 1.66B |
---|---|---|---|---|---|
Net income 2024 * | -14M -1.31M - -103M | Net income 2025 * | -4M -373K - -29.4M | EV / Sales 2024 * | 3.19 x |
Net cash position 2024 * | 10.3M 961K 0 75.69M | Net cash position 2025 * | 11M 1.03M 0 80.84M | EV / Sales 2025 * | 2.33 x |
P/E ratio 2024 * |
-15.8
x | P/E ratio 2025 * |
-54.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.56% |
Latest transcript on SENN AB
Managers | Title | Age | Since |
---|---|---|---|
Peter Nählstedt
CEO | Chief Executive Officer | 50 | 31/12/17 |
Marianne Olsson
DFI | Director of Finance/CFO | 63 | 31/10/16 |
Henrik Johansson
CTO | Chief Tech/Sci/R&D Officer | 42 | 31/12/13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 76 | 17/08/10 | |
Director/Board Member | 59 | 14/10/14 | |
Paula Zeilon
BRD | Director/Board Member | 62 | 31/12/19 |
1st Jan change | Capi. | |
---|---|---|
-31.90% | 9.59B | |
-6.25% | 3.21B | |
+25.95% | 2.92B | |
-13.96% | 2.15B | |
-16.83% | 1.79B | |
+72.82% | 1.47B | |
+29.17% | 770M | |
-2.62% | 761M | |
-26.33% | 548M |